WST
West Pharmaceutical ServicesDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Bull: successful execution on capacity expansion, steady margin improvement, and one or more favorable analyst upgrades that re-rate multiples; supports material upside versus the anchor within 12 months.
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-07-22 · BMO.
What can break
Analyst downgrades / multiple compression
Momentum
63
Value
60
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.19 · Bull $22.10 · Bear $8.29
Earnings
2026-07-22 · BMO
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-15 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $390.71
Why
Momentum63 · Δ7d -4.5
Value60 · Δ7d 0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
63
26% active weight
Current posture
7d trendSoftening
Δ7d
-4.5
Δ21d
-23.4
Value
60
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.1
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 63.2 / Value 60.0 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$25.31B
Beta
1.18
Shares Out
70.65M
P/E (TTM)
41.3
P/S (TTM)
6.65
P/FCF (TTM)
63.05
Rev YoY
+21.0%
EPS YoY
+55.8%
Gross Margin
+36.3%
Op Margin
+19.5%
Net Debt
-$465.1M
Current Ratio
2.71
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology